Format

Send to

Choose Destination
See comment in PubMed Commons below
Intensive Crit Care Nurs. 2008 Feb;24(1):59-62. Epub 2007 Aug 14.

Rasburicase in the prevention and treatment of tumour lysis syndrome.

Author information

1
Paediatric and Adolescent Services, University College London Hospitals NHS Foundation Trust, London, UK.

Abstract

Tumour lysis syndrome (TLS) can be a life threatening complication of cancer therapy where cells undergo overwhelming lysis. The result is a pattern of metabolic abnormalities leading to acute renal failure and possible coagulopathy. Prophylactic pharmaceutical interventions can prevent this syndrome in almost all patients reducing possible admission to the intensive care unit. This article reviews the clinical efficacy, side effect profile, dosing and administration of rasburicase, an intravenous recombinant urate oxidase used in patients at risk of Tumour lysis syndrome due to a high tumour burden or where treatment is required. Rasburicase is an expensive but effective treatment option in the prevention and treatment of tumour lysis syndrome.

PMID:
17698360
DOI:
10.1016/j.iccn.2007.06.002
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center